Actively Recruiting

Phase Not Applicable
Age: 18Years - 70Years
All Genders
NCT06394063

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients

Led by RenJi Hospital · Updated on 2024-07-03

176

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a randomized, double-blind, placebo-controlled single-center clinical trial. The aim of this study is to investigate the efficacy and safety of low-dose telitacicept for prevention of flares in SLE patients with low disease activity.

CONDITIONS

Official Title

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-70 years
  • Diagnosed with systemic lupus erythematosus (SLE) with low disease activity (SELENA-SLEDAI score less than 8 at screening)
  • Disease duration more than 3 months with no severe BILAG A score and no more than one B score
  • Stable treatment regimen with fixed doses of prednisone (up to 30 mg/day), antimalarial, or immunosuppressive drugs for at least 3 months
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Hepatic or renal dysfunction: ALT/AST greater than 2 times upper normal limits or GFR less than 60 ml/min
  • Exposure to cyclophosphamide within 6 months before screening
  • Exposure to any B cell targeted therapy (Rituximab, Belimumab, Telitacicept) within 6 months before screening
  • Pregnant or lactating women
  • History of malignancy within the last 5 years, except treated skin tumors or carcinoma in situ of cervix
  • Active hepatitis or history of severe liver disease
  • Current infections such as HIV, tuberculosis, or COVID-19 at screening
  • Significant decrease in immunoglobulin level (IgG less than 5 g/L)
  • Not suitable for the study as judged by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ren Ji Hospital

Shanghai, China, 201112

Actively Recruiting

Loading map...

Research Team

T

Ting Li

CONTACT

S

Shuang Ye

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here